HB2638 Summary

• Prescribers must offer naloxone hydrochloride or FDA-approved opioid reversal drug to patients when prescription dosage is 90 or more morphine milligram equivalents per day.

• Prescribers must offer naloxone or alternative reversal drug when opioid medication is prescribed concurrently with benzodiazepines.

• Prescribers must offer naloxone or alternative reversal drug to patients with increased overdose risk, including those with history of overdose, substance use disorder, or risk of returning to high opioid doses.

• Prescribers must provide education on overdose prevention and naloxone use to eligible patients and designated persons or parents/guardians of minor patients.

• Prescriptions to inmates or youth in Department of Corrections or Department of Juvenile Justice custody are exempt; non-compliance subjects prescribers to administrative sanctions but does not create private lawsuits; effective January 1, 2020.